- Market Capitalization, $K 839,085
- Shares Outstanding, K 54,878
- Annual Sales, $ 0 K
- Annual Income, $ -103,230 K
- 60-Month Beta -0.95
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 3.38
|Period||Period Low||Period High||Performance|
| || |
+2.91 (+23.74%)since 12/23/19
| || |
+9.10 (+149.51%)since 10/23/19
| || |
-8.09 (-34.73%)since 01/23/19
- Enrollment target achieved for rilonacept Phase 3 trial in recurrent pericarditis; top-line data expected in 2H 2020 -
The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals
The biotech sector was in focus this week with pipeline and regulatory updates from quite a few players.
Gilead (GILD) collaborates with Kiniksa for a combination study and submits BLA for CAR T therapy candidate.
Kite, a Gilead Company (Nasdaq: GILD), and Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) ("Kiniksa") announced today that the companies have entered into a clinical collaboration to conduct a Phase 2, multicenter...
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa, will present at the 38 Annual J.P. Morgan Healthcare Conference...
Companies in the news are: URBN, KNSA, ACB, ENDP
The U.S. Food and Drug Administration (FDA) as part of its mission, is responsible for protecting the public health by assuring the safety, effectiveness, and security of human drugs, vaccines and medical...
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2 Annual Evercore ISI HealthCONx Conference on Wednesday, December 4, 2019 at 3:30 p.m. Eastern Time at the Four...
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) ("Kiniksa"), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant...